NanoViricides Inc. (NNVC)

[changes_iv]

About US organized medicine (ahem) and ICPT and NNVC...it is another Puffer-like example (among others) on how these breakthrough technologies can skyrocket in pps with no products in the market!

The stock of a little-known biotech company, Intercept Pharmaceuticals Inc., ICPT +59.89% nearly quadrupled Thursday after the company's liver-disease drug performed well in a clinical trial, marking the biggest one-day stock leap among Nasdaq Composite companies of a similar size since at least 2012.

Shares of New York-based Intercept—which has 45 employees and no products on the market—closed Thursday at $275.87 on the Nasdaq Stock Market, valuing the company at $5.3 billion. On Wednesday, the stock closed at $72.39 with a market capitalization of $1.4 billion.

That's the largest one-day jump among Nasdaq Composite companies with market values of over $1 billion since at least 2012, according to FactSet Research Systems Inc.

The drug, called obeticholic acid, or OCA, mimics a naturally occurring human bile acid that Intercept believes has insert-text-here. The National Institute of Diabetes and Digestive and Kidney Diseases sponsored a clinical trial of the drug in patients with a condition known as nonalcoholic steatohepatitis, which involves fat accumulation in the liver that can cause inflammation and lead to the more serious conditions of cirrhosis and liver failure. The disease progresses over many years and often has no symptoms in the early stages.

There are no specific therapies for the disease, which affects 2% to 5% of Americans, according to the National Institutes of Health. Instead, physicians often recommend patients lose weight if they are overweight, improve their diets, exercise, and avoid alcohol and unnecessary medications.

source: http://online.wsj.com/news/articles/SB10001424052702304347904579310212798133916

NanoViricides, Inc. is being thorough and is on the move!!!

WEST HAVEN, Conn.--(BUSINESS WIRE)--Jul 23, 2012 - NanoViricides, Inc. (OTC BB: NNVC) (the "Company") announced today that it has retained Australian Biologics Pty. Ltd., a regulatory affairs consulting firm, to coordinate the regulatory review and approval to conduct the first human trials in Australia for Flucide™, the Company's broad-spectrum anti-influenza drug. Australian Biologics will also facilitate clinical trial site(s) selection and development of the clinical trials agreements.

source: http://www.drugs.com/clinical_trials/nanoviricides-retains-consulting-firm-expedite-first-flucide-human-trials-australia-14091.html

Nothing is static in economies and markets. As NanoViricides, Inc. progresses on-track to clinical trials, and progress is communicated via PRs, pps will climb higher. Just like ICPT, first $30 pps and higher, around $70 pps, sounds good, IMHO. We should be given breakthrough technology FAST TRACK (good for flying horses) once the GLP evidence is presented by BASi, in Indiana. We will see an explosion in pps, or KaBOOM. around first quarter of 2014!!! You ain't seen nothing yet!!!...but we will this year and next...and the following years!!!

Puffer, if you are reading this and when possible, please post, to all on this board, other examples. I cannot locate those posts unless I start to go through them one-by-one. I know, I should have bookmarked them. Thanks in advance.